OBSTRUCTIVE SLEEP APNEA SURVEILLANCE AND ORAL APPLIANCE THERAPY EVALUATION, ACTIVE DUTY

U.S. ARMY, 2014-2019

LTC Christa E. Goodwin, DMD, MS¹
Tyson L. Grier, MS²
Olivia M. Mahlmann, MPH³

¹Tri-Service Center for Oral Health Studies, 2787 Winfield Scott Road, Joint Base San Antonio - Fort Sam Houston, TX 78234
²U.S. Army Public Health Center, 8977 Sibert Road, APG, MD 21010
³Armed Forces Health Surveillance Branch, Defense Health Agency, 8977 Sibert Road, APG, MD 21010

Disclaimer: The views expressed in this publication are those of the authors and do not necessarily reflect the official policy or position of the Department of the Army, the Department of Defense, or the U.S. Government. The mention of any non-federal entity and/or its products is for informational purposes only, and not to be construed or interpreted, in any manner, as federal endorsement of that non-federal entity or its products.
**Abstract:**

**Objective:** Determine the incidence of obstructive sleep apnea (OSA) among Army Soldiers from 2014 through 2019 and assess self-reported impacts of the disorder and one of its treatments - oral appliance therapy.

**Methods:** Surveillance data were obtained from Armed Forces Health Surveillance Division; remaining data were self-reported through an electronic survey.

**Results:** There were 87,404 cases of OSA from 2014 through 2019; incidence rates ranged from 274.3 to 330.3 cases per 10,000 person-years (p-yrs). Male incidence rates (from 294.3 to 355.9/10,000 p-yrs) exceeded female incidence rates (from 155.2 to 189.2/10,000 p-yrs). Soldiers ≥40 years old had the highest incidence rates (from 820.1 to 973.2/10,000 p-yrs). The survey was completed by 8,740 Soldiers. The majority reported positive airway pressure therapy as their current treatment method; 9 percent (n=795) reported treatment with the oral appliance. Comparing pre-to post-treatment, respondents treated with the oral appliance reported statistically significant improvements in sleep quality, duration, and various aspects of daily life. The predominance (76%) of those treated with anything other than the oral appliance reported they were not aware of the oral appliance as a treatment method.

**Conclusions:** Results suggest Soldiers are satisfied with the oral appliance; it has significantly improved their sleep quality, duration, and various aspects of daily life.

**Clinical Implications:** Military dentists can pave the way for a streamlined process when it comes to the diagnosis and treatment of OSA. The required yearly dental exam provides an opportunity to screen Soldiers for OSA and discuss the lesser-known treatment - oral appliance therapy.

**Key words:**

obstructive sleep apnea; oral appliance therapy; Army; military; Soldiers
Introduction:

Obstructive sleep apnea (OSA), the most common sleep-related breathing disorder, is a rising health concern among the military population. Characterized by recurring episodes of upper airway obstruction or narrowing during sleep, OSA is frequently associated with obesity and a large neck circumference. Troubling comorbidities affiliated with this disorder include hypertension, heart failure, atrial fibrillation, pulmonary hypertension, coronary heart disease, and stroke. The pathologic process of OSA is rather convoluted as both anatomic and mechanical components contribute to the collapsibility of the upper airway. This collapse results in disordered breathing events including apneas, hypopneas, and respiratory event-related arousals. Typical signs and symptoms of OSA include excessive daytime sleepiness, loud snoring, gasping, insomnia, and nocturia.

Poor sleep quality introduces various health and safety risks including fatigue, depression, impaired physical and cognitive performance, diminished alertness, and an increased risk of motor vehicle crashes. Considering the high prevalence of OSA, the associated comorbidities and health and safety risks, as well as the accompanying financial implications, this disorder can be considered a significant public health concern.

The gold standard diagnostic test for OSA is an in-laboratory polysomnogram (PSG). However, home sleep apnea tests (HSATs) are increasingly being utilized as they are a more accessible, less costly method for diagnosing OSA in adults. The severity of OSA is quantified by the apnea-hypopnea index (AHI) – the number of apneas and hypopneas measured per hour of sleep. Obstructive apneas are characterized by the cessation, or near-cessation, of airflow despite respiratory effort; more specifically, airflow is decreased to less than 10% of the baseline during an obstructive apnea. Hypopneas, however, are a partial reduction in airflow and further defined as a 30% to 90% airflow reduction. Consequences of obstructive apneas and hypopneas during sleep include intermittent hypoxemia, changes in intrathoracic pressure, and sleep arousal. An AHI of less than 5 is considered normal; AHI of
5-14.9 indicates mild OSA; AHI of 15-29.9 is moderate; AHI of 30 or greater indicates severe OSA.\textsuperscript{2-5}

There are a myriad of risk factors for OSA, a major factor being elevated body mass index (BMI).\textsuperscript{2-3} Although, OSA can occur in individuals of normal BMI as well. OSA is most common among men between young adulthood and middle age; however, it can occur at any age, in both males and females.\textsuperscript{2-3} Additional risk factors include menopause, enlarged upper airway soft tissues (e.g., tonsils, tongue), and craniofacial abnormalities (e.g., retrognathia).\textsuperscript{2-3}

The impact of OSA on Soldiers and their readiness to deploy is exceptionally relevant, as quality sleep is critical to their mission performance. Treatment options for OSA include positive airway pressure (PAP) therapy, oral appliance therapy, and surgery.\textsuperscript{2,3,5} Adjunctive behavioral-related interventions include weight loss, exercise, and positional therapy.\textsuperscript{2,3,5} PAP therapy remains the gold standard treatment for OSA; however, it requires a great deal of maintenance and can be challenging to adhere to.\textsuperscript{9} Additionally, deployment to austere locations may make the logistical task of utilizing and maintaining the PAP extremely difficult. Acceptable adherence to PAP therapy is defined as 4 hours of use per night, at least 5 nights per week.\textsuperscript{3} A 2015 investigation concluded that military personnel with OSA have low adherence to PAP, with 60.3\% of study participants found to be nonadherent.\textsuperscript{9}

Oral appliance therapy is an effective treatment for mild and moderate OSA.\textsuperscript{10-14} Moreover, those suffering from severe OSA have seen improvements in health outcomes while using the oral appliance,\textsuperscript{14} something particularly relevant to those who are intolerant to PAP therapy. This small and lightweight appliance may be a more practical treatment method for Soldiers with OSA given the nature of the military profession; it presents with an ease of use that has the ability to improve Soldier readiness.

This project serves as both a surveillance and treatment method evaluation. The purpose is threefold: determine the incidence of OSA among active duty Army Soldiers from 2014 through 2019; assess the identified Soldiers’ subjective, self-reported impacts of this
disorder and one of its treatment methods - oral appliance therapy; and assess Soldiers’ compliance and satisfaction with the oral appliance.

**Methods:**

The U.S. Army Public Health Center (APHC) Public Health Review Board (PHRB) approved this surveillance evaluation and survey as public health practice; it was assigned project #19-744.

**Surveillance**

The surveillance data were obtained from the Armed Forces Health Surveillance Division (AFHSD). Data analyses were restricted to active duty Army Soldiers diagnosed with OSA from 2014 through 2019. The following case definition was developed by AFHSD for the purpose of epidemiological surveillance:

- One hospitalization with any of the defining diagnoses of OSA (Table 1) in any diagnostic position; or
- Two outpatient medical encounters within 90 days of each other, with any of the defining diagnoses of OSA (Table 1) in any diagnostic position.

For individuals who met the case definition:

- The incident date was considered the date of the first hospitalization or outpatient medical encounter that included a defining diagnosis of OSA.
- An individual was considered an incident case only *once per lifetime*.

Analysis of surveillance data was conducted using Microsoft® Excel® 2016. Yearly incidence rates were estimated by dividing the number of incident diagnoses by the number of active duty Army Soldiers reported in Defense Medical Epidemiology Database (DMED) for that particular year. Incidence rates were further stratified by sex, age group, and rank.

A discrepancy was found in the surveillance data following the initial stages of analysis. An inconsistency in the number of identified cases led to a re-investigation of the data
requisition. It was determined that the incidence rule listed above (once per lifetime) was not initially taken into account by AFHSD. As such, prevalent cases were not excluded, and our case list consisted of some individuals who had initially been diagnosed with OSA prior to the surveillance period (2014-2019). This affected our survey population, as the survey was distributed prior to the identification of this problem.

A new data requisition, including the ‘once per lifetime’ incidence rule, was completed; the surveillance findings presented below reflect this. Following a cross-reference of the survey respondents’ identities with the list of cases, it was determined that 15% (N=1,307) of the survey respondents were Soldiers initially diagnosed with OSA prior to 2014. Soldiers’ self-reported impacts of this disorder and its treatment are extremely relevant to the Army, regardless of the diagnosis year. Accordingly, it was decided that all feedback should be included in this report.

Survey

The survey was published in Verint®, a secure electronic survey platform. Email addresses for Soldiers diagnosed with OSA during the surveillance period were obtained from the Defense Manpower Data Center (DMDC). The intent was to electronically distribute the survey to all previously identified Soldiers; however, email addresses were only available in DMDC for 34% (n=37,162) of the identified Soldiers. On 30 September 2020, an email containing the link to the survey was sent to the 37,162 Soldiers. Over the next several months, Soldiers who had not yet completed the survey received email reminders. The survey closed on 28 December 2020.

The survey began with three exclusion questions; it immediately ended for those that did not consent, reported they were no longer active duty, or reported they were not diagnosed with OSA during the specified time frame (2014-2019). Next, demographics including age, sex, rank, and military occupational specialty (MOS) were obtained. In addition, Soldiers were asked to
report physical characteristics (height, weight), OSA severity, deployment eligibility, OSA
treatment method(s) discussed with provider(s), and current OSA treatment method(s).

The most effective treatment plans for managing OSA and other sleep-related breathing
disorders are multidisciplinary and comprehensive.\textsuperscript{11} Therefore, Soldiers had the option to
select multiple methods. Soldiers that reported treatment with anything other than the oral
appliance were asked if they were aware of oral appliance therapy prior to taking the survey.

The following section gave Soldiers the opportunity to rate the impact of OSA on several
subjective measures of everyday wellness (measured on a 5-point Likert scale) prior to initiating
any form of treatment, including sleep quality and duration, daily performance, cognitive level,
alertness, level of physical activity, fatigue, and daytime sleepiness. The survey ended for those
that reported treatment with any method other than the oral appliance. For Soldiers that
reported treatment with the oral appliance (either exclusively, or in conjunction with other
treatment modalities) the survey continued with an evaluation of treatment compliance and
satisfaction. Soldiers were again asked to rate the impacts on everyday wellness (sleep quality
and duration, cognition, alertness, physical activity, daytime sleepiness, etc.); however, they
were instructed to consider the impact post-treatment with the oral appliance for at least 1
month. The period of 1 month was selected as the oral appliance may require some
adjustments in the first several weeks following delivery.

There is no standardized definition of oral appliance adherence within the dental sleep
medicine community, and no validated questionnaire exists to measure adherence.\textsuperscript{15} A
definition for adherence was established specifically for this study. Adherence was defined as
wearing the oral appliance for at least 80\% of an average night of sleep, calculated by dividing
the reported average number of hours the oral appliance was worn per night by the reported
average number of hours slept per night. Adherence did not take into account the reported
number of nights per week the oral appliance was used. This is because in the open-ended
question of the survey, numerous Soldiers indicated that the oral appliance was used as an
‘alternate therapy’ when deployed (or traveling), as they were unable to use the CPAP in those environments due to unreliable electricity and/or inability to obtain maintenance supplies, for example.

Data analyses were conducted using SPSS® Version 21.0 and Open Source Epidemiologic Statistics for Public Health, Version 3.01. Missing or invalid responses were excluded. Means and standard deviations for height and weight were calculated and stratified by sex. Body Mass Index (BMI) was calculated based on the height and weight reported at the time the survey was taken, not at the time of disorder diagnosis. The following formula was utilized: \((weight (lb) \div height (in)^2)\times703\). Frequencies were calculated by sex for the following: age, BMI, rank, disorder severity, deployment eligibility, treatment method(s) discussed with provider(s), current treatment method(s), and awareness of the oral appliance prior to taking survey. Soldiers that reported any airway pressure device as current method of treatment were included in the ‘PAP therapy’ group for all analyses. These devices included the following: continuous positive airway pressure (CPAP), average volume-assured pressure support (AVAP), auto-adjustable positive airway pressure (APAP), adaptive-servo ventilation (ASV) device, and bi-level positive airway pressure (BiPAP).

Shapiro-Wilk normality tests were conducted, indicating that the data were not normally distributed; nonparametric tests were thus used for subsequent analysis of the survey data. Wilcoxon Signed-Rank tests were used to evaluate differences in pre-to post-treatment variable ratings by sex and reported treatment method. Pre-to post-treatment comparisons were made among several different groups of Soldiers based on reported treatment method(s), including those treated with both the oral appliance and PAP therapy, those treated exclusively with the oral appliance, and those treated with the oral appliance (either exclusively or in combination with any other method). Results of all comparisons can be found in the full technical report approved by the APHC and published on the Defense Technical Information Center - Technical Report No. S.0079064.3-21. However, this specific publication focuses only on the
comparisons made among the latter group of Soldiers (i.e., Soldiers that reported treatment with
the oral appliance, either exclusively, or in combination with any other method). Consistent with
convention, an alpha level of 0.05 was used as the cut off for defining statistical significance,
(i.e., p ≤ 0.05).

There were no pre-to post treatment comparisons made among Soldiers who did not
report treatment with the oral appliance. The purpose of this evaluation was not to compare the
oral appliance to PAP therapy, or to any other treatment method. For this reason, those that
reported treatment with anything other than the oral appliance received a shortened survey.

**Results:**

**Surveillance**

There were 87,404 incident diagnoses of OSA among active Army Soldiers from the
years 2014 through 2019. Incidence rates for the Army overall and by sex are illustrated in
Figure 1. Table 2 lists incidence rates of OSA by year, sex, age, and rank. Yearly incidence
rates for the Army overall ranged from 274.3 to 330.3 cases per 10,000 p-yrs. The number of
male cases (n=80,323) far exceeded that of female cases (n=7,081). Male incidence rates (from
294.3 to 355.9 cases per 10,000 p-yrs) also exceeded that of females (from 155.2 to 189.2
cases per 10,000 p-yrs). Men comprised 91.9% of all OSA cases during this study period, and
as of 2020, 84.6% of the Army (Table 3).

The greatest proportion (36.2%) of all OSA cases occurred among Soldiers ≥ 40 years
of age. As of 2020, this age group comprised the smallest proportion (10.9%) of the Army
(Table 3). Soldiers ≥40 years of age had the highest incidence rates of any other age group
(from 820.1 to 973.2 cases per 10,000 p-yrs); Soldiers ≤ 20 years of age had the lowest rates
(from 6.4 to 14.9 cases per 10,000 p-yrs) (Table 2).

The greatest proportion (57.4%) of all OSA cases occurred among Soldiers in the ranks
of E5-E9 (Table 3). As of 2020, those in the ranks of O4-O10 comprised the smallest proportion
(6.7%) of the active Army yet had the highest incidence rates (from 487.6 to 715.4 cases per
10,000 p-yrs) (Table 2). Soldiers in the ranks of E1-E4 had the lowest incidence rates ranging from 115.6 to 145.6 cases per 10,000 p-yrs.

**Survey**

The survey was sent electronically to 37,162 Soldiers; email addresses for all identified cases could not be located. The survey was initiated by 12,090 Soldiers for an initial response rate of 33%. However, the survey was not completed by all that initiated it. Those that answered ‘No’ to one or more of the exclusion questions were immediately excluded, as were Soldiers that exited prior to completing the entire survey. The final number of Soldiers that submitted the survey totaled 8,740 (24%).

Table 4 displays the reported demographics, OSA severities, deployment eligibilities, and treatment methods of survey respondents. The majority of survey respondents were men (95%; n=8,269) between 41 and 50 years of age (45%; n=3930) in the Enlisted (E) ranks of E4 through E9 (63%; n=5469). Fifty-three percent (n=4298) and 51% (n=241) of male and female survey respondents, respectively, were considered overweight; 40% (n=3255) and 26% (n=121) were considered obese. The vast majority (93%; 402 women, 7,726 men) reported treatment with PAP therapy, either in combination with other treatment modalities, or exclusively. Nine percent of Soldiers (n=795; 85 women, 710 men) reported treatment with the oral appliance. Of these Soldiers treated with the oral appliance, 45% (n=360; 41 women, 319 men) were treated with it exclusively; the remaining reported a combination of the oral appliance and other treatments modalities (e.g., PAP therapy, lifestyle changes, medication, etc.). The majority of Soldiers that reported treatment with anything other than the oral appliance (76%; n=5,234) reported they were not aware of oral appliance therapy as a treatment for OSA prior to taking the survey.

The majority (43%) of respondents reported moderate OSA. Twenty-eight percent reported severe OSA; 13% were unaware of the severity of their disorder. The vast majority of survey respondents (63%, n=5,466) indicated that deployment eligibility was not impacted by
disorder diagnosis; 16% (n=1,470) reported that a waiver was required for deployment. Of the Soldiers that reported treatment with the oral appliance, 88% were considered adherent to the treatment; adherence among men (88%) was equal to that of women (88%).

Figure 2 illustrates the proportion of adherent and non-adherent oral appliance users that reported side effects (teeth shifting, bite changes, jaw soreness) following treatment. A greater proportion of non-adherent users reported teeth shifting, bite changes, and jaw soreness compared adherent users. The most common reported side effect, reported by 70% of adherent oral appliance users and 84% of non-adherent users, was jaw soreness.

Figure 3 illustrates oral appliance overall satisfaction and comfort ratings of all Soldiers treated with the appliance, regardless of adherence. On a scale of 1 to 5 (1-not at all satisfied; 5-completely satisfied), 29% (n=218) of Soldiers rated satisfaction a 3; 30% (n=221) rated satisfaction a 4. On a scale of 1 to 5 (1-extremely uncomfortable; 5-extremely comfortable), 37% (n=280) rated comfort a 3; 24% (n=177) rated it a 4.

Table 5 displays the pre-to post treatment comparisons of male and female Soldiers adherent to the oral appliance. All Soldiers reported statistically significant improvements (p≤0.001) in all wellness variables (sleep duration and quality, cognition, alertness, physical activity, fatigue, etc.). The wellness variable with the greatest percent improvement among both men and women was sleep quality (69% for men, 60% for women). The variable with the least percent improvement among women was physical activity (15%); among men both sleep duration (17%) and physical activity (17%) had the least percent improvement.

At the conclusion of the OSA survey, Soldiers were presented with an open-ended question that provided them with the opportunity to share any additional information they chose regarding their experiences, diagnoses, treatments, etc. Many Soldiers (n=1,280) took advantage of this opportunity and chose to provide very lengthy comments. However, the discussion of these comments, including their relevance, deserves more space than permitted in this publication. Therefore, the open-ended comments will be reviewed and discussed at
length in a separate commentary report. Alternatively, they can be reviewed in the APHC Technical Report No. S.0079064.3-21.\textsuperscript{17}

**Discussion:**

**Surveillance**

OSA constitutes a significant burden to our Soldiers, with 87,404 diagnoses from 2014 through 2019. The year-to-year incidence rates exhibited minor fluctuations during this period; however, there has been a considerable rise in OSA diagnoses over the last 15 years.\textsuperscript{1,17} According to one study\textsuperscript{1}, the incidence of OSA among active Army Soldiers increased 600% from 2004 to 2013. Likewise, the percentage of those classified as overweight or obese has been increasing throughout the years. In a study of active duty personnel, the combined overweight and obesity prevalence increased from 50.6% in 1995 to 60.8% in 2008.\textsuperscript{18} Additionally, an investigation of Army recruits showed a 19% increase in body fat mass among both men and women from 1975 to 2013.\textsuperscript{19} The increase in overweight and obese Soldiers may have contributed to the increase in OSA diagnoses throughout the years. Additionally, a greater awareness of this disorder, its symptoms, and its risk factors may have led to a greater number of PSG referrals, and ultimately a greater number of diagnoses.

OSA is more common among men, both in the general population and active Army. The vast majority of the cases (92%) were among male Soldiers. Given the gender distribution in the Army, this is to be expected. Nevertheless, when assessing risk, male Soldiers consistently had higher incidence rates compared to female Soldiers. OSA is a result of upper airway collapse during sleep. It has been suggested that the higher prevalence of OSA among men may be attributed to the sex-related differences in the structure and physiological behavior of the upper airway.\textsuperscript{20} Literature shows that women have augmented genioglossal muscle activity compared to men, as well as a different upper airway shape.\textsuperscript{20} This increased activity results in greater upper airway stability, making upper airway closure during sleep less likely.\textsuperscript{20}
In the general population, OSA is most commonly diagnosed between young adulthood and middle age. The vast majority of active duty Army Soldiers (89%) are 39 years of age or younger. Soldiers 40 years or older comprise the smallest proportion of the Army (11%), yet this age group experienced the greatest proportion of cases (36%) and the highest incidence rates. Therefore, while the preponderance of active Army Soldiers is under the age of 40, those over 40 have a substantially higher risk of OSA diagnosis. As discussed previously, obesity is a major risk factor for OSA. Consequently, the sex and age distribution of obesity among active Army Soldiers is highly relevant when considering the sex and age distribution of OSA among active Army Soldiers. The last three iterations of the APHC’s Health of the Force Report\textsuperscript{21-23} stated that 17\% of active Army Soldiers were obese; the prevalence of obesity increased with age, and in all age groups men were more likely to be obese than women. Therefore, the higher rates of OSA among older male Soldiers may be associated with the higher likelihood of obesity among this group.

As of 2019, Enlisted Soldiers represented the vast majority of the Army (80\%); predictably, this group represented the greatest proportion of OSA diagnoses during this study period (77.0\%). However, when considering risk, Officers in the ranks of O4 through O10 had the highest incidence rates. This greater risk may be attributed to the differing age distributions among ranks. As of 2020, almost a third (29\%) of Officers were 40 years or older while only 7\% of Enlisted Soldiers were in this age group.

Survey

Follow-up PSGs are very useful for determining the efficacy of treatment (i.e., how well it works under ideal, controlled conditions). However, they do not measure the treatment’s effectiveness (i.e., how well it performs in real world conditions). Therefore, this survey was designed to assess Soldiers’ subjective, self-reported impacts of OSA and oral appliance therapy, as well as their compliance and satisfaction with this treatment. The initial survey response rate of 33\% suggests that OSA is an important matter among Soldiers.
Considering the longevity and proven efficacy of PAP therapy, it was not surprising that the vast majority of Soldiers reported treatment with the PAP device. However, the responses in the open-ended question indicated that some Soldiers alternate treatment methods (i.e., use of PAP therapy at home and oral appliance during deployments or when traveling), while others use them in conjunction with each other. This is not unusual, as the alternating of treatments may help to minimize side effects of either therapy.

**Deployment Eligibility and OSA Severity**

According to the minimum standards of fitness for deployment, Soldiers with symptomatic OSA and/or moderate to severe OSA require waivers to deploy, yet the majority of survey respondents (63%) indicated that deployment eligibility was not impacted by OSA diagnosis. However, a Soldier may not be aware of deployment eligibility until the time he/she is assigned to deploy.

OSA severity was self-reported and unable to be validated, a distinct limitation of this study. Similar to deployment eligibility, Soldiers may not be aware of the severity of their disorder, as it is based on the AHI index measured during the PSG. Some likely based the severity of their disorder using a subjective view of the severity of the impact on day-to-day life.

**Adherence**

The vast majority (88%) of oral appliance users were considered adherent to the treatment. However, it must be reiterated that there is no standardized definition of oral appliance adherence; the determination of adherence included the use of a definition constructed specifically for this investigation.

Adherence to treatment may be based on a multitude of factors, including side effects experienced, as well as overall comfort and satisfaction with the treatment. The majority of oral appliance users rated overall appliance satisfaction as 4 (1-not at all satisfied; 5-completely satisfied); the majority rated overall appliance comfort as 3 (1-extremely uncomfortable; 5-extremely comfortable). Although, when assessing side effects by treatment adherence, a
greater proportion of non-adherent Soldiers reported side effects from the appliance (teeth shifting, bite changes, and jaw soreness) compared to adherent Soldiers. This finding is to be expected, as patients experiencing side effects from a prescribed treatment would be less likely to comply with it.

**Pre-to Post-Treatment Wellness Comparisons**

This report focuses on all Soldiers treated with the oral appliance, exclusively or in combination with other treatments. The results of this survey demonstrate that the oral appliance has significantly improved their sleep quality and duration, as well as other wellness-related aspects of daily life (e.g., alertness, cognition, daily performance, etc.). However, in our complete investigation, those treated exclusively with the oral appliance were separated from those treated with both the PAP device and oral appliance. Similar results were found; both groups reported statistically significant improvements in all wellness variables pre-to post-treatment. Although, when observing the percent change in the wellness ratings pre-to post-treatment, the improvement was greater for those treated with the oral appliance and PAP, compared to those treated exclusively with the oral appliance. These findings suggest that combination therapy may provide more relief than just the oral appliance alone. However, whether or not those treated with both the oral appliance and PAP therapy alternated the treatments, or used them in conjunction with each other, is unknown.

**Awareness**

The first modern oral appliances for the treatment of OSA were developed in 1982. Despite the fact that oral appliance therapy is not a newly developed treatment method, it has taken a backseat to PAP therapy for many years, most likely due to lack of awareness. The vast majority (76%, n=5,234) of Soldiers who reported any treatment method other than the oral appliance indicated they were not aware of this treatment prior to taking the survey. Perhaps some medical providers do not discuss oral appliance therapy with Soldiers because they themselves are not aware of it, or they do not believe it is an effective method for treating this
disorder. Nevertheless, the oral appliance may gain more attention since Philips Respironics, a principal military PAP device supplier, recently issued a device recall. This recall notification was released four months after the close of the survey. Therefore, the specific impact the recall had, and continues to have on Soldiers suffering from OSA is unknown at this time.

Military dentists have an opportunity to pave the way for a streamlined process when it comes to the diagnosis and treatment of OSA. While a dentist cannot officially diagnose this disorder, the required yearly dental exam provides the dentist with the opportunity to screen Soldiers for it. Additionally, the information that is routinely gathered during comprehensive dental examinations (e.g., health of hard and soft tissues of the mouth, location and integrity of teeth, etc.) will help determine if a patient is a candidate for the oral appliance, should that patient be diagnosed with OSA in the future. The creation of this collaborative nature between dentists and physicians will serve to simplify and improve the OSA diagnostic and treatment processes.

The Military Health System (MHS) Quadruple Aim represents the ultimate goal for the MHS - to ensure a medically ready force through better health, better care, and lower cost. Oral appliances are much less expensive to provide when compared to a PAP device. A recent study outlined the potential cost savings for the military that oral appliance therapy offers. There were roughly 4,800 oral appliances issued Army-wide between August 2016 and August 2020, the cost of which was $2.1 million. Had the PAP device been issued to those patients instead of the oral appliance, the cost would have been $4.8 million. Ultimately, oral appliance therapy aligns with the MHS Quadruple Aim by successfully treating OSA, thereby improving readiness and deployability, at a lower financial cost.

Limitations

The utilization of ICD diagnostic codes for surveillance studies, in any position, comes with limitations. These codes may not always translate into an official diagnosis. This was evident once the survey was administered to the Soldiers who were previously identified as
OSA cases. Numerous Soldiers (n=71) responded to the survey via email indicating they did not have OSA. Some reported they had been tested for it in the past, after which they were informed that they did not have OSA. Some Soldiers indicated they were diagnosed with other sleep-related disorders (e.g. restless leg syndrome, insomnia, etc.), while others reported that if they did in fact have OSA, they were never informed of it. When these 71 Soldiers were cross referenced with the list of cases provided by AFHSD, it was determined that 18% of them did not display the OSA diagnostic code in the primary diagnostic position, but instead in a higher position (i.e., second through fourth positions). Therefore, the position of the ICD code may be of relevance when attempting to determine the true incidence (or prevalence) of a medical disorder or disease.

Self-reported studies, in general, present with multiple validity problems including the following: respondents may exaggerate symptoms, they may under- or over-report frequencies, or they may simply misremember specific details. Therefore, while it was very important to capture Soldiers’ subjective, self-reported burdens of this disorder, and their comfort and satisfaction with treatment, the confines of this specific type of study are well recognized and appreciated.

**Conclusions and recommendations**

Quality sleep is critical to mission readiness. It is a valuable contributor to mental and physical health and provides the body with an opportunity to restore and rejuvenate itself. Consequences of poor sleep quality include emotional distress, impaired cognition, risk of injury, and multiple other short- and long-term health complications. Unfortunately, sleep-related breathing disorders among Soldiers are not uncommon. Additionally, the nature of the profession presents with many sleep-related challenges.

This report demonstrates that OSA remains a prevalent disorder, notably among older Army Soldiers. To our knowledge, this is the first survey assessing Soldiers’ subjective burdens from this sleep disorder, as well as their compliance and satisfaction with oral appliance
therapy. The efficacy of PAP therapy has been thoroughly studied and proven; it remains the gold standard treatment. However, it is expensive, requires a great deal of maintenance, and can be challenging to adhere to.\(^9\) For many, PAP therapy is difficult to adhere to under ideal circumstances; in a deployed environment, its use can be thoroughly burdensome and inconvenient. Oral appliance therapy is an effective treatment that can be used as an alternative to, or in conjunction with, PAP therapy.\(^{10-14}\) The oral appliance is small, lightweight, and requires no electricity. Its ease of use, particularly in austere locations, provides it with the ability to improve Soldier readiness.

This survey indicates that overall, Soldiers are satisfied with oral appliance therapy. Additionally, this treatment has significantly improved their sleep quality, duration, and various aspects of daily life. It was noteworthy to discover that the vast majority of Soldiers managed by methods other the oral appliance were not aware of the oral appliance as a treatment method for OSA. This finding in addition to the multitude of comments recounting the struggles of receiving a diagnosis and effective treatment indicate there are some barriers within the military health care system.\(^{16}\) Consequently, an assessment of the current processes for screening, diagnosis, and treatment of Soldiers with sleep-related breathing disorders is well founded. Army Dentistry has the opportunity to support Army Medicine in the streamlining of these processes. Ultimately, evaluation of long-term oral appliance therapy outcomes and cost-savings analyses may benefit the military and Soldiers with OSA.

**References:**


9. Mysliwiec V; Capaldi V; Gill J; Baxter T, O’Reilly B, Matsangas P; Roth B. Adherence to positive airway pressure therapy in the U.S. military personnel with sleep apnea improves sleepiness, sleep quality, and depressive symptoms. *Military Medicine.* 2015;180(4):475-482.


https://www.usa.philips.com/healthcare/e/sleep/communications/src-update

Table 1. ICD-9/ICD-10 diagnostic codes for obstructive sleep apnea

<table>
<thead>
<tr>
<th>Description</th>
<th>ICD-9 code</th>
<th>ICD-10 code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obstructive sleep apnea, adult, pediatric</td>
<td>327.23</td>
<td>G47.33</td>
</tr>
<tr>
<td>Sleep apnea, unspecified</td>
<td>780.51, 780.57</td>
<td>G47.30</td>
</tr>
<tr>
<td>Other sleep apnea</td>
<td>780.53</td>
<td>G47.39</td>
</tr>
</tbody>
</table>

ICD, International Classification of Diseases

Table 2. OSA incidence rates* by sex, age, and rank, active duty U.S. Army, 2014-2019

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall Army</td>
<td>290.4</td>
<td>312.7</td>
<td>330.3</td>
<td>300.8</td>
<td>274.3</td>
<td>318.4</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>312.1</td>
<td>336.9</td>
<td>355.9</td>
<td>324.2</td>
<td>294.3</td>
<td>341.5</td>
</tr>
<tr>
<td>Female</td>
<td>155.2</td>
<td>165.8</td>
<td>179.5</td>
<td>166.4</td>
<td>160.4</td>
<td>189.2</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;20</td>
<td>6.4</td>
<td>10.3</td>
<td>8.3</td>
<td>12.5</td>
<td>11.5</td>
<td>14.9</td>
</tr>
<tr>
<td>20-24</td>
<td>73.9</td>
<td>89</td>
<td>89.4</td>
<td>85.6</td>
<td>81.5</td>
<td>107.6</td>
</tr>
<tr>
<td>25-29</td>
<td>188.9</td>
<td>209.7</td>
<td>214.9</td>
<td>193.7</td>
<td>183.7</td>
<td>224.7</td>
</tr>
<tr>
<td>30-34</td>
<td>320.3</td>
<td>344.9</td>
<td>357.4</td>
<td>314.2</td>
<td>289.8</td>
<td>342.5</td>
</tr>
<tr>
<td>35-39</td>
<td>522.4</td>
<td>570.1</td>
<td>600.8</td>
<td>567.7</td>
<td>517.7</td>
<td>616.6</td>
</tr>
<tr>
<td>≥40</td>
<td>820.1</td>
<td>856.6</td>
<td>973.2</td>
<td>941.7</td>
<td>888</td>
<td>972.4</td>
</tr>
<tr>
<td>Rank</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E1-E4</td>
<td>139.3</td>
<td>145</td>
<td>145.6</td>
<td>129.9</td>
<td>115.6</td>
<td>142.1</td>
</tr>
<tr>
<td>E5-E9</td>
<td>452.9</td>
<td>494.3</td>
<td>527.8</td>
<td>482.9</td>
<td>421.7</td>
<td>474.3</td>
</tr>
<tr>
<td>O1-O3(W1-W3)</td>
<td>209.5</td>
<td>234.4</td>
<td>264.4</td>
<td>238.9</td>
<td>235.3</td>
<td>262.1</td>
</tr>
<tr>
<td>O4-O10(W4-W5)</td>
<td>487.6</td>
<td>524</td>
<td>606.1</td>
<td>582.2</td>
<td>596.4</td>
<td>715.4</td>
</tr>
</tbody>
</table>

*rates per 10,000 person-years; OSA, obstructive sleep apnea; E, enlisted; O, officer; W, warrant officer
<table>
<thead>
<tr>
<th>Sex</th>
<th>% of OSA Cases&lt;sup&gt;a&lt;/sup&gt;</th>
<th>% of Army Population&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>91.9</td>
<td>84.6</td>
</tr>
<tr>
<td>Female</td>
<td>8.1</td>
<td>15.4</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;20</td>
<td>0.3</td>
<td>7.5</td>
</tr>
<tr>
<td>20-24</td>
<td>8.6</td>
<td>30.7</td>
</tr>
<tr>
<td>25-29</td>
<td>15.2</td>
<td>23.6</td>
</tr>
<tr>
<td>30-34</td>
<td>17.5</td>
<td>15.4</td>
</tr>
<tr>
<td>35-39</td>
<td>22.3</td>
<td>11.9</td>
</tr>
<tr>
<td>≥40</td>
<td>36.2</td>
<td>10.9</td>
</tr>
<tr>
<td>Rank</td>
<td></td>
<td></td>
</tr>
<tr>
<td>E1-E4</td>
<td>19.6</td>
<td>43.1</td>
</tr>
<tr>
<td>E5-E9</td>
<td>57.4</td>
<td>37.4</td>
</tr>
<tr>
<td>O1-O3(W1-W3)</td>
<td>10.1</td>
<td>12.8</td>
</tr>
<tr>
<td>O4-O10(W4-W5)</td>
<td>12.9</td>
<td>6.7</td>
</tr>
</tbody>
</table>

OSA, obstructive sleep apnea
<sup>a</sup>2014-2019; <sup>b</sup>as of 2020, reported in Defense Medical Epidemiology Database
<table>
<thead>
<tr>
<th></th>
<th>Men (N=8,269)</th>
<th>Women (N=471)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N (%)</td>
<td>N (%)</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20-30</td>
<td>480 (6)</td>
<td>43 (9)</td>
</tr>
<tr>
<td>31-40</td>
<td>3,302 (40)</td>
<td>139 (30)</td>
</tr>
<tr>
<td>41-50</td>
<td>3,712 (45)</td>
<td>218 (46)</td>
</tr>
<tr>
<td>51-69</td>
<td>775 (9)</td>
<td>71 (15)</td>
</tr>
<tr>
<td>BMI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Underweight/normal (18.5-25.9)</td>
<td>584 (7)</td>
<td>109 (23)</td>
</tr>
<tr>
<td>Overweight (25.0-29.9)</td>
<td>4,298 (53)</td>
<td>241 (51)</td>
</tr>
<tr>
<td>Obese (30.0+)</td>
<td>3,255 (40)</td>
<td>121 (26)</td>
</tr>
<tr>
<td>Disorder severity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild</td>
<td>1,302 (16)</td>
<td>135 (29)</td>
</tr>
<tr>
<td>Moderate</td>
<td>3,540 (43)</td>
<td>205 (43)</td>
</tr>
<tr>
<td>Severe</td>
<td>2,343 (28)</td>
<td>74 (16)</td>
</tr>
<tr>
<td>Unknown</td>
<td>1,084 (13)</td>
<td>57 (12)</td>
</tr>
<tr>
<td>Deployment eligibility</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eligibility not impacted by diagnosis</td>
<td>5,151 (63)</td>
<td>315 (67)</td>
</tr>
<tr>
<td>Waiver necessary to deploy</td>
<td>1,430 (17)</td>
<td>40 (9)</td>
</tr>
<tr>
<td>Not eligible to deploy</td>
<td>94 (1)</td>
<td>11 (2)</td>
</tr>
<tr>
<td>Eligibility unknown</td>
<td>1,594 (19)</td>
<td>105 (22)</td>
</tr>
<tr>
<td>Current treatment method(s)b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive airway pressure therapyc</td>
<td>7,726 (93)</td>
<td>402 (85)</td>
</tr>
<tr>
<td>Oral appliance therapy</td>
<td>710 (9)</td>
<td>85 (18)</td>
</tr>
<tr>
<td>Lifestyle changes</td>
<td>1,134 (14)</td>
<td>70 (15)</td>
</tr>
<tr>
<td>Not treated</td>
<td>11 (&lt;1)</td>
<td>1 (&lt;1)</td>
</tr>
<tr>
<td>Other</td>
<td>161 (2)</td>
<td>18 (4)</td>
</tr>
<tr>
<td>Awareness of oral appliance therapy prior to surveyd</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>1,590 (24)</td>
<td>63 (19)</td>
</tr>
<tr>
<td>No</td>
<td>4,972 (76)</td>
<td>262 (81)</td>
</tr>
</tbody>
</table>

N includes only valid responses

*BMI Body Mass Index calculated from height/weight reported in survey

*Respondents could choose more than one current treatment method

*Includes all positive airway pressure devices: CPAP, AVAP, ASV, BPAP

*This question only applied to respondents who did not select oral appliance therapy as current treatment method or treatment method discussed with provider
Table 5. Comparison of pre-to-post treatment wellness ratings by sex, adherent* oral appliance users

<table>
<thead>
<tr>
<th>Wellness Variable</th>
<th>Men Before</th>
<th>Men After</th>
<th>Change in Mean (%)</th>
<th>Women Before</th>
<th>Women After</th>
<th>Change in Mean (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N Median; Mean±SD</td>
<td>Median; Mean±SD</td>
<td></td>
<td>N Median; Mean±SD</td>
<td>Median; Mean±SD</td>
<td></td>
</tr>
<tr>
<td>Sleep qualitya</td>
<td>572 2; 1.96±.90</td>
<td>3; 3.32±.98</td>
<td>69</td>
<td>64 2; 2.0±.96</td>
<td>3; 3.20±.86</td>
<td>60</td>
</tr>
<tr>
<td>Hours of sleep Per night</td>
<td>519 5; 5.19±1.1</td>
<td>6; 6.08±1.1</td>
<td>17</td>
<td>51 4; 4.78±1.0</td>
<td>5.5; 5.56±1.0</td>
<td>16</td>
</tr>
<tr>
<td>Performanceb</td>
<td>572 3; 2.91±1.0</td>
<td>4; 3.69±.96</td>
<td>27</td>
<td>64 3; 2.80±.95</td>
<td>3; 3.52±.87</td>
<td>26</td>
</tr>
<tr>
<td>Cognitionc</td>
<td>572 3; 2.98±1.1</td>
<td>4; 3.72±.96</td>
<td>25</td>
<td>64 3; 2.83±.99</td>
<td>4; 3.55±.99</td>
<td>25</td>
</tr>
<tr>
<td>Alertnessd</td>
<td>572 3; 2.99±.99</td>
<td>4; 3.69±.94</td>
<td>23</td>
<td>64 3; 2.89±.98</td>
<td>4; 3.63±.97</td>
<td>26</td>
</tr>
<tr>
<td>Physical activitye</td>
<td>572 3; 3.17±1.1</td>
<td>4; 3.72±1.0</td>
<td>17</td>
<td>64 3; 3.03±1.0</td>
<td>3; 3.48±.93</td>
<td>15</td>
</tr>
<tr>
<td>Fatiguef</td>
<td>572 2; 1.88±.92</td>
<td>3; 2.92±1.0</td>
<td>55</td>
<td>64 2; 1.86±.94</td>
<td>3; 2.86±.91</td>
<td>54</td>
</tr>
<tr>
<td>Excessive daytime sleepinessf</td>
<td>568 2; 2.09±1.0</td>
<td>3; 3.09±1.1</td>
<td>48</td>
<td>64 2; 2.20±1.1</td>
<td>3; 2.97±.99</td>
<td>35</td>
</tr>
<tr>
<td>Feeling restedg</td>
<td>572 2; 2.16±.78</td>
<td>3; 3.16±.92</td>
<td>46</td>
<td>63 2; 2.02±.87</td>
<td>3; 2.89±.91</td>
<td>43</td>
</tr>
</tbody>
</table>

*Respondents considered adherent if they reported wearing the appliance ≥ 80% of an average night of sleep; includes those treated with the oral appliance exclusively or in combination with any other method. N includes only valid responses.

Wilcoxon Signed-Rank used to compare before and after ratings; all differences statistically significant p ≤ 0.001

All scales 5-point Likert: a1-extremely poor 5-excellent; b1-extremely difficult 5-no difficulty; c1-cognition extremely impaired 5-normal cognition; d1-severe lack of alertness 5-highly alert; e1-extremely difficult 5-no difficulty; f1-most days 5-never; g1-never 5-always.
Figure 2. Reported side effects from oral appliance therapy, adherent and non-adherent oral appliance users

Adherent users = 636
Non-adherent users = 117
Missing or invalid responses = 42

- Teeth shifting: 37% (Adherent), 44% (Non-adherent)
- Bite changes: 44% (Adherent), 48% (Non-adherent)
- Jaw soreness: 70% (Adherent), 84% (Non-adherent)
Figure 3. Oral appliance therapy satisfaction and comfort ratings, all oral appliance users

- Satisfaction N=751
  - Missing or invalid responses=44
- Comfort N=753
  - Missing or invalid responses=42

Percent of all appliance users:

- 1: Not at all satisfied
  - Extremely uncomfortable
- 2: Satisfied
- 3: Very satisfied
- 4: extremely satisfied
- 5: Completely satisfied

- Satisfaction:
  - 1: 15%
  - 2: 17%
  - 3: 14%
  - 4: 18%
  - 5: 29%

- Comfort:
  - 1: 12%
  - 2: 24%
  - 3: 30%
  - 4: 24%
  - 5: 37%